Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study testing a new treatment called TK-6302 for the first time in people with advanced cancers that have a genetic marker called HLA-A02:01 and a tumour protein called PRAME.

Next Previous
Trial Profile

A study testing a new treatment called TK-6302 for the first time in people with advanced cancers that have a genetic marker called HLA-A02:01 and a tumour protein called PRAME.

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TK 6302 (Primary)
  • Indications Endometrial cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Skin cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Acronyms ATLAS
  • Sponsors T-Knife

Most Recent Events

  • 17 Mar 2026 New source identified and integrated (Clinical Trials Information System).
  • 03 Mar 2026 According to the T-knife Media Release, The company confirmed that its Clinical Trial Application (CTA) has been approved to initiate the trial in Europe.
  • 02 Mar 2026 Status changed from planning to not yet recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top